Despite the fact that circulating IGF2 concentration is not strongly associated with AD risk, understanding the blood‐to‐brain transport mechanisms may be important for developing IGF2 therapeutics that reliably deliver the peptide into the brain. This evidence concerns the gene IGF2 and Alzheimer disease.